Avidity Biosciences RNA 深 滬
等待開盤 01-12 09:30:00 美东时间
72.37
0.000
0.00%
華盛通- 最 高72.41
- 今 開72.33
- 成交量 112.22万股
- 最 低 72.30
- 昨 收 72.37
- 總市值 109.28亿
- 52周最高 72.61
- 市盈率 靜 --
- 換手率 0.74%
- 52周最低 21.51
- 委 比 -0.04%
- 總股本 1.51亿
- 歷史最高 72.61
- 量 比 0.40
- 振 幅 0.15%
- 歷史最低 4.825
- 每 手 1
- 風險率 15.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity
Oppenheimer upgraded Dyne Therapeutics (DYN) on Wednesday, citing a positive read-through from data that Novartis’ (NVS) buyout target Avidity Biosciences (RNA) is set to release this year from a late...
2025-12-11 02:43
诺华宣布收购Avidity Biosciences
诺华近日宣布达成一项协议，将收购Avidity Biosciences, Inc.，这是一家位于圣地亚哥的生物制药公司、专注于开发一种能将RNA递送至肌肉的新型...
2025-11-25 17:44
Avidity Biosciences Announces MAP For Investigational Therapy Delpacibart Zotadirsen For Eligible People With Duchenne Muscular Dystrophy Mutations Amenable To Exon 44 Skipping In US
Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access
2025-11-19 22:15
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonuc...
2025-11-19 22:13
Momentum movers: 10 stocks surging over 40% over the last month
Despite lingering uncertainty in the broader market following recent selloffs, investor enthusiasm has not been entirely dampened. In fact, several large-cap stocks have surged sharply, with some clim...
2025-11-13 02:12
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
Chardan Capital Maintains Neutral on Avidity Biosciences, Maintains $72 Price Target
Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Neutral and maintains $72 price target.
2025-11-11 20:59
Avidity Biosciences Q3 EPS $(1.27) Misses $(1.11) Estimate, Sales $12.475M Beat $1.932M Estimate
Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(1.11) by 13.9 percent. This is a 95.38 percent decrease over losses of $(0.65) per share
2025-11-11 05:24
Key deals this week: Qorvo, Chewy, Sotherly Hotels, Novartis, CSG Systems, and more
Here's a list of key deals reported across sectors this week: Skyworks Solutions (SWKS), which supplies radio frequency chips to Apple (AAPL) and other smartphone makers, has agreed to buy Qorvo (NASD...
2025-11-02 03:15
美股周涨跌榜 | RNA周内大涨42.1%！获诺华120亿美元收购；阿根廷概念股全线飙升
RNA周内大涨42.1%，获诺华120亿美元收购；阿根廷概念股全线飙升，SUPV涨84.5%、END涨71.9%>>
2025-11-01 10:35
